Status and phase
Conditions
Treatments
About
Safety and efficacy of direct thrombin inhibitors versus enoxaparin in patients with staphylococcus aureus bacteraemia.
The study hypothesizes that inhibition of the coagulase-activity of S. aureus by direct thrombin inhibitors is safe and translates into a better outcome of patients with S. aureus bacteremia.
Full description
Single center randomized controlled trial of direct thrombin inhibitors versus standard enoxaparin.
Feasibility: proportion of patients eligible for randomization; clinically attained concentration of DTI and resulting staphylothrombin inhibition
Safety: bleeding events (major/ clinically relevant non-major)
Efficacy: thrombotic events during the thromboprophylactic treatment + 3 days
Secondary outcome measures
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
94 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal